Revolutionary nasal spray offers hope by potentially delaying Alzheimer's progression through cutting-edge neurological ...

A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...

They then used the nasal spray on several mouse models and observed them over time to see if it made a difference. The research team found that the mice exhibited reduced dementia symptoms.

A major trial in frontotemporal dementia patients has found that oxytocin can help improve symptoms of apathy. A new study ...

Patients were given two daily treatments of oxytocin through nasal spray, every third day for six weeks by their ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

An anti-Alzheimer's nasal spray that could delay the progress of ... Alzheimer's is the most common form of dementia, and the leading cause of death among those aged 65 or older and afflicts ...

Researchers delivered a dose of the “love hormone” oxytocin via a nasal spray to participants and found that it decreased ...

The Food and Drug Administration (FDA) approved Johnson & Johnson’s ketamine-derived nasal spray to help millions of U.S.

The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major ...

Jan. 21 (UPI) --The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression. Johnson & Johnson's Spravato has been approved to treat a ...